| Name | Title | Contact Details |
|---|
We are the leading, global mid-sized contract research organization. Our team of more than 4,200 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.
Goodroot is a community of companies committed to reinventing healthcare one system at a time. Our mission is to reshape how our current system operates and make healthcare more affordable and more accessible for all. We develop and leverage businesses that not only improve the current state of healthcare delivery, but that also reform or replace the most critical parts of the system that are no longer working. Goodroot offers and sells the full range of products and services of all brands and companies underneath our umbrella to offer the most idealistic approach of capabilities for our clients. With a growing group of brands including RemedyOne, AlignRx, Penstock, Famulus, CoeoRx and ScholarScripts, Goodroot aims to helps everyone from pharmacy management to payment integrity and everyone in between.
Laxai is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.